237 related articles for article (PubMed ID: 25865752)
21. Effects of fluvastatin extended-release (80 mg) alone and in combination with ezetimibe (10 mg) on low-density lipoprotein cholesterol and inflammatory parameters in patients with primary hypercholesterolemia: a 12-week, multicenter, randomized, open-label, parallel-group study.
Alvarez-Sala LA; Cachofeiro V; Masana L; Suarez C; Pinilla B; Plana N; Trias F; Moreno MA; Gambus G; Lahera V; Pintó X
Clin Ther; 2008 Jan; 30(1):84-97. PubMed ID: 18343245
[TBL] [Abstract][Full Text] [Related]
22. [ACUTE CORONARY SYNDROME AND LIPID-LOWERING THERAPY. DOES THE IMPROVE-IT STUDY MAKE ANY DIFFERENCE?].
Lancellotti P; Pierard LA; Scheen AJ
Rev Med Liege; 2015 Sep; 70(9):450-5. PubMed ID: 26638446
[TBL] [Abstract][Full Text] [Related]
23. Lowering low-density lipoprotein cholesterol: statins, ezetimibe, bile acid sequestrants, and combinations: comparative efficacy and safety.
Hou R; Goldberg AC
Endocrinol Metab Clin North Am; 2009 Mar; 38(1):79-97. PubMed ID: 19217513
[TBL] [Abstract][Full Text] [Related]
24. Evidence for cholesterol hyperabsorbers and hyperproducers based on comparative low-density lipoprotein reductions achieved by ezetimibe versus statins.
Senaratne J; Griffiths J; MacDonald K; Senaratne MP
J Cardiopulm Rehabil Prev; 2012; 32(5):250-4. PubMed ID: 22785146
[TBL] [Abstract][Full Text] [Related]
25. Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: a pooled analysis of over 21,000 subjects from 27 clinical trials.
Morrone D; Weintraub WS; Toth PP; Hanson ME; Lowe RS; Lin J; Shah AK; Tershakovec AM
Atherosclerosis; 2012 Aug; 223(2):251-61. PubMed ID: 22410123
[TBL] [Abstract][Full Text] [Related]
26. The impact of ezetimibe and high-dose of statin treatment on LDL levels in patients with heterozygous familial hypercholesterolemia.
Pitsavos C; Skoumas I; Tousoulis D; Metalinos G; Masoura C; Chrysohoou C; Papadimitriou L; Giotsas N; Toutouza M; Antoniades C; Stefanadis C
Int J Cardiol; 2009 May; 134(2):280-1. PubMed ID: 18353459
[TBL] [Abstract][Full Text] [Related]
27. Sociodemographic and diagnostic characteristics of prescribing a second-line lipid-lowering medication: ezetimibe used as initial medication, switch from statins, or add-on medication.
Wallach-Kildemoes H; Hansen EH
Eur J Clin Pharmacol; 2015 Oct; 71(10):1245-54. PubMed ID: 26227068
[TBL] [Abstract][Full Text] [Related]
28. [Optimal cholesterol levels in patients in real-life. A systematic review].
Escobar C; Barrios V; Pérez de Isla L
Semergen; 2018; 44(1):42-49. PubMed ID: 29153337
[TBL] [Abstract][Full Text] [Related]
29. Effects of ezetimibe on plasma lipoproteins in severely hypercholesterolemic patients treated with regular LDL-apheresis and statins.
Geiss HC; Otto C; Hund-Wissner E; Parhofer KG
Atherosclerosis; 2005 May; 180(1):107-12. PubMed ID: 15823282
[TBL] [Abstract][Full Text] [Related]
30. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
Sahebkar A; Watts GF
Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
[TBL] [Abstract][Full Text] [Related]
31. Combination therapy analysis of ezetimibe and statins in Chinese patients with acute coronary syndrome and type 2 diabetes.
Li L; Zhang M; Su F; Li Y; Shen Y; Shen J; Zhang D
Lipids Health Dis; 2015 Feb; 14():10. PubMed ID: 25879728
[TBL] [Abstract][Full Text] [Related]
32. [Up to date lipid lowering treatment].
Paragh G; Karádi I
Orv Hetil; 2016 Jul; 157(31):1219-23. PubMed ID: 27476517
[TBL] [Abstract][Full Text] [Related]
33. Intestinal sterol transporters and cholesterol absorption inhibition.
Davis HR; Tershakovec AM; Tomassini JE; Musliner T
Curr Opin Lipidol; 2011 Dec; 22(6):467-78. PubMed ID: 22101558
[TBL] [Abstract][Full Text] [Related]
34. Attainment of LDL-Cholesterol Treatment Goals in Patients With Familial Hypercholesterolemia: 5-Year SAFEHEART Registry Follow-Up.
Perez de Isla L; Alonso R; Watts GF; Mata N; Saltijeral Cerezo A; Muñiz O; Fuentes F; Diaz-Diaz JL; de Andrés R; Zambón D; Rubio-Marin P; Barba-Romero MA; Saenz P; Sanchez Muñoz-Torrero JF; Martinez-Faedo C; Miramontes-Gonzalez JP; Badimón L; Mata P;
J Am Coll Cardiol; 2016 Mar; 67(11):1278-85. PubMed ID: 26988947
[TBL] [Abstract][Full Text] [Related]
35. [Ezetimibe in clinical practice: from laboratory investigations to the IMPROVE-IT trial results].
Borghi C; Filardi PP
G Ital Cardiol (Rome); 2015; 16(7-8 Suppl 1):3S-14S. PubMed ID: 26442834
[TBL] [Abstract][Full Text] [Related]
36. Statin and ezetimibe combination therapy in cardiovascular disease.
Dembowski E; Davidson MH
Curr Opin Endocrinol Diabetes Obes; 2009 Apr; 16(2):183-8. PubMed ID: 19262375
[TBL] [Abstract][Full Text] [Related]
37. Combination therapy.
Denke MA
J Manag Care Pharm; 2003; 9(1 Suppl):17-9. PubMed ID: 14613355
[TBL] [Abstract][Full Text] [Related]
38. [Statin and absorption inhibitor work synergistically. More risk patient reach LDL cholesterol goal value].
MMW Fortschr Med; 2007 Apr; 149(17):56-7. PubMed ID: 17674912
[No Abstract] [Full Text] [Related]
39. A 10-year experience using combined lipid-lowering pharmacotherapy in children and adolescents.
Araujo MB; Pacce MS
J Pediatr Endocrinol Metab; 2016 Nov; 29(11):1285-1291. PubMed ID: 27718491
[TBL] [Abstract][Full Text] [Related]
40. Safety and efficacy of ezetimibe added on to rosuvastatin 5 or 10 mg versus up-titration of rosuvastatin in patients with hypercholesterolemia (the ACTE Study).
Bays HE; Davidson MH; Massaad R; Flaim D; Lowe RS; Tershakovec AM; Jones-Burton C
Am J Cardiol; 2011 Aug; 108(4):523-30. PubMed ID: 21596364
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
